SEC Info - Cell MedX Corp. - ‘10-Q’ for 8/31/14

SEC Info℠

Home

My Interests

Help

Please Sign In

Cell MedX Corp. – ‘10-Q’ for 8/31/14 – ‘EX-101.DEF’

On: Wednesday, 10/8/14, at 6:16pm ET · As of: 10/9/14 · For: 8/31/14 · Accession #: 1594062-14-314 · File #: 0-54500

Previous ‘10-Q’: ‘10-Q/A’ on 7/17/14 for 2/28/14 · Next: ‘10-Q’ on 1/14/15 for 11/30/14 · Latest: ‘10-Q’ on 4/15/24 for 2/29/24 · 20 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/09/14  Cell MedX Corp.                   10-Q        8/31/14   37:2.9M                                   Ideal Connection, Inc/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report -- form10q                         HTML    136K 
 2: EX-3.2      Articles of Merger ? Sports Asylum, Inc. and        HTML     16K 
                Plandel Resources, Inc.*                                         
 3: EX-3.3      Articles of Merger ? Cell Medx Corp. and Sports     HTML     16K 
                Asylum, Inc.*                                                    
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     20K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     17K 
23: R1          Document and Entity Information                     HTML     40K 
17: R2          Condensed Balance Sheets (Unaudited)                HTML     52K 
21: R3          Condensed Balance Sheets (Parenthetical)            HTML     21K 
25: R4          Condensed Statements of Operations (Unaudited)      HTML     30K 
34: R5          Condensed Statements of Cash Flows (Unaudited)      HTML     45K 
18: R6          Note 1 - Organization                               HTML     23K 
20: R7          Note 2 - Summary of Significant Accounting          HTML     19K 
                Policies                                                         
16: R8          Note 3 - Unproved Mineral Claim                     HTML     16K 
14: R9          Note 4 - Definitive Letter Agreement                HTML     18K 
35: R10         Note 5 - Advances Payable                           HTML     17K 
27: R11         Note 6 - Significant Transactions With Related      HTML     19K 
                Parties                                                          
26: R12         Note 7 - Common Stock                               HTML     22K 
30: R13         Note 8 - Going Concern                              HTML     18K 
31: R14         Note 9 - Subsequent Events                          HTML     18K 
29: R15         Note 2 - Summary of Significant Accounting          HTML     17K 
                Policies (Policies)                                              
32: R16         Note 1 - Organization (Details Narrative)           HTML     19K 
22: R17         Note 3 - Unproved Mineral Claim (Details            HTML     15K 
                Narrative)                                                       
24: R18         Note 4 - Definitive Letter Agreement (Details       HTML     24K 
                Narrative)                                                       
28: R19         Note 5 - Advances Payable (Details Narrative)       HTML     17K 
37: R20         Note 6 - Significant Transactions With Related      HTML     20K 
                Parties (Details Narrative)                                      
33: R21         Note 8 - Going Concern (Details Narrative)          HTML     18K 
19: R22         Note 9 - Subsequent Events (Details Narrative)      HTML     18K 
36: XML         IDEA XML File -- Filing Summary                      XML     47K 
12: EXCEL       IDEA Workbook of Financial Reports                  XLSX     33K 
15: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS     57K 
 8: EX-101.INS  XBRL Instance -- sylm-20140831                       XML     76K 
 6: EX-101.CAL  XBRL Calculations -- sylm-20140831_cal               XML     52K 
 7: EX-101.DEF  XBRL Definitions -- sylm-20140831_def                XML     33K 
 9: EX-101.LAB  XBRL Labels -- sylm-20140831_lab                     XML    175K 
10: EX-101.PRE  XBRL Presentations -- sylm-20140831_pre              XML    127K 
11: EX-101.SCH  XBRL Schema -- sylm-20140831                         XSD     50K 
13: ZIP         XBRL Zipped Folder -- 0001594062-14-000314-xbrl      Zip     22K

‘EX-101.DEF’ — XBRL Definitions — sylm-20140831_def

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://SYLM/role/DocumentAndEntityInformation" xlink:href="sylm-20140831.xsd#DocumentAndEntityInformation" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/BalanceSheets" xlink:href="sylm-20140831.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/BalanceSheetsParenthetical" xlink:href="sylm-20140831.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/StatementsOfOperations" xlink:href="sylm-20140831.xsd#StatementsOfOperations" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/StatementsOfCashFlows" xlink:href="sylm-20140831.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note1-Organization" xlink:href="sylm-20140831.xsd#Note1-Organization" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note2-SummaryOfSignificantAccountingPolicies" xlink:href="sylm-20140831.xsd#Note2-SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note3-UnprovedMineralClaim" xlink:href="sylm-20140831.xsd#Note3-UnprovedMineralClaim" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note4-DefinitiveLetterAgreement" xlink:href="sylm-20140831.xsd#Note4-DefinitiveLetterAgreement" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note5-AdvancesPayable" xlink:href="sylm-20140831.xsd#Note5-AdvancesPayable" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note6-SignificantTransactionsWithRelatedParties" xlink:href="sylm-20140831.xsd#Note6-SignificantTransactionsWithRelatedParties" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note7-CommonStock" xlink:href="sylm-20140831.xsd#Note7-CommonStock" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note8-GoingConcern" xlink:href="sylm-20140831.xsd#Note8-GoingConcern" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note9-SubsequentEvents" xlink:href="sylm-20140831.xsd#Note9-SubsequentEvents" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sylm-20140831.xsd#Note2-SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note1-OrganizationDetailsNarrative" xlink:href="sylm-20140831.xsd#Note1-OrganizationDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note3-UnprovedMineralClaimDetailsNarrative" xlink:href="sylm-20140831.xsd#Note3-UnprovedMineralClaimDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note4-DefinitiveLetterAgreementDetailsNarrative" xlink:href="sylm-20140831.xsd#Note4-DefinitiveLetterAgreementDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note5-AdvancesPayableDetailsNarrative" xlink:href="sylm-20140831.xsd#Note5-AdvancesPayableDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note6-SignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:href="sylm-20140831.xsd#Note6-SignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note8-GoingConcernDetailsNarrative" xlink:href="sylm-20140831.xsd#Note8-GoingConcernDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://SYLM/role/Note9-SubsequentEventsDetailsNarrative" xlink:href="sylm-20140831.xsd#Note9-SubsequentEventsDetailsNarrative" xlink:type="simple"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note1-Organization" xlink:title="00000006 - Disclosure - NOTE 1 - ORGANIZATION"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note2-SummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note3-UnprovedMineralClaim" xlink:title="00000008 - Disclosure - NOTE 3 - UNPROVED MINERAL CLAIM"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note4-DefinitiveLetterAgreement" xlink:title="00000009 - Disclosure - NOTE 4 - DEFINITIVE LETTER AGREEMENT"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note5-AdvancesPayable" xlink:title="00000010 - Disclosure - NOTE 5 - ADVANCES PAYABLE"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note6-SignificantTransactionsWithRelatedParties" xlink:title="00000011 - Disclosure - NOTE 6 - SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note7-CommonStock" xlink:title="00000012 - Disclosure - NOTE 7 - COMMON STOCK"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note8-GoingConcern" xlink:title="00000013 - Disclosure - NOTE 8 - GOING CONCERN"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note9-SubsequentEvents" xlink:title="00000014 - Disclosure - NOTE 9 - SUBSEQUENT EVENTS"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note2-SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000015 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note1-OrganizationDetailsNarrative" xlink:title="00000016 - Disclosure - NOTE 1 - ORGANIZATION (Details Narrative)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note3-UnprovedMineralClaimDetailsNarrative" xlink:title="00000017 - Disclosure - NOTE 3 - UNPROVED MINERAL CLAIM (Details Narrative)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note4-DefinitiveLetterAgreementDetailsNarrative" xlink:title="00000018 - Disclosure - NOTE 4 - DEFINITIVE LETTER AGREEMENT (Details Narrative)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note5-AdvancesPayableDetailsNarrative" xlink:title="00000019 - Disclosure - NOTE 5 - ADVANCES PAYABLE (Details Narrative)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note6-SignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:title="00000020 - Disclosure - NOTE 6 - SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note8-GoingConcernDetailsNarrative" xlink:title="00000021 - Disclosure - NOTE 8 - GOING CONCERN (Details Narrative)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://SYLM/role/Note9-SubsequentEventsDetailsNarrative" xlink:title="00000022 - Disclosure - NOTE 9 - SUBSEQUENT EVENTS (Details Narrative)"/>

</link:linkbase>

20 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/15/24  Cell MedX Corp.                   10-Q        2/29/24   53:2.7M                                   Empire Stock Transf… Inc
 1/16/24  Cell MedX Corp.                   10-Q       11/30/23   46:2.3M                                   Empire Stock Transf… Inc
10/16/23  Cell MedX Corp.                   10-Q        8/31/23   42:1.9M                                   Empire Stock Transf… Inc
 9/01/23  Cell MedX Corp.                   10-K        5/31/23   73:3.2M                                   Empire Stock Transf… Inc
 6/29/23  Cell MedX Corp.                   10-Q        2/28/23   53:2.5M                                   Empire Stock Transf… Inc
 5/19/23  Cell MedX Corp.                   10-Q       11/30/22   53:2.4M                                   Empire Stock Transf… Inc
 4/19/23  Cell MedX Corp.                   10-Q        8/31/22   51:2.2M                                   Empire Stock Transf… Inc
 4/07/23  Cell MedX Corp.                   10-K        5/31/22   90:3.6M                                   Empire Stock Transf… Inc
 4/11/22  Cell MedX Corp.                   10-Q        2/28/22   56:2.5M                                   Empire Stock Transf… Inc
 1/12/22  Cell MedX Corp.                   10-Q       11/30/21   54:2.4M                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   424B3                  1:365K                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   10-Q        8/31/21   50:2.2M                                   Empire Stock Transf… Inc
10/12/21  Cell MedX Corp.                   424B3                  1:705K                                   Empire Stock Transf… Inc
 8/30/21  Cell MedX Corp.                   10-K        5/31/21   83:3.7M                                   Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   424B3                  1:501K                                   Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   10-Q        2/28/21   56:2.8M                                   Empire Stock Transf… Inc
 3/04/21  Cell MedX Corp.                   S-1                   78:3.8M                                   Empire Stock Transf… Inc
 1/14/21  Cell MedX Corp.                   10-Q       11/30/20   53:2M                                     Empire Stock Transf… Inc
10/15/20  Cell MedX Corp.                   10-Q        8/31/20   51:1.9M                                   Empire Stock Transf… Inc
 9/15/20  Cell MedX Corp.                   10-K        5/31/20   84:2.9M                                   Empire Stock Transf… Inc

↑Top